Tian-Yi Jiang

Tian-Yi Jiang

Auto-generated profile, based on publicly available information

Tian-Yi Jiang

International Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer The Naval Medical University Shanghai China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
TJTian-Yi Jiang
Tian-Yi Jiang
YPYu-Fei Pan
Yu-Fei Pan
ZWZheng-Hua Wan
Zheng-Hua Wan
YLYun-Kai Lin
Yun-Kai Lin
BZBin Zhu
Bin Zhu
HWHongyang Wang
Hongyang Wang
PTEN loss promotes the expression of genes encoding proteasome subunits and facilitates bortezomib chemosensitivity.

12 July 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
TJTian-Yi Jiang
Tian-Yi Jiang
XCXiao-Wen Cui
Xiao-Wen Cui
TZTian-Mei Zeng
Tian-Mei Zeng
YPYu-Fei Pan
Yu-Fei Pan
YLYun-Kai Lin
Yun-Kai Lin
HWHongyang Wang
Hongyang Wang
Gemcitabine is a nucleoside analog that has been successfully used in the treatment of multiple cancers. However, intrinsic or acquired resistance reduces the chemotherapeutic potential of gemcitabine. Here, we revealed a previously unappreciated mechanism by which phosphatase and tensin homolog (PTEN), one of the most frequently mutated genes in human cancers, dominates the decision-making process that is central to the regulation of gemcitabine efficacy in cholangiocarcinoma (CCA). By investigating a gemcitabine-treated CCA cohort, we found that PTEN deficiency was correlated with the improved efficacy of gemcitabine-based chemotherapy. Using cell-based drug sensitivity assays, cell line–derived xenograft, and patient-derived xenograft models, we further confirmed that PTEN deficiency or genetic-engineering down-regulation of PTEN facilitated gemcitabine efficacy both in vitro and in vivo. Mechanistically, PTEN directly binds to and dephosphorylates the C terminus of the catalytic subunit of protein phosphatase 2A (PP2Ac) to increase its enzymatic activity, which further dephosphorylates deoxycytidine kinase (DCK) at Ser 74 to diminish gemcitabine efficacy. Therefore, PTEN deficiency and high phosphorylation of DCK predict a better response to gemcitabine-based chemotherapy in CCA. We speculate that the combination of PP2A inhibitor and gemcitabine in PTEN-positive tumors could avoid the resistance of gemcitabine, which would benefit a large population of patients with cancer receiving gemcitabine or other nucleoside analogs.

18 May 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
SLShuang-Xi Li
Shuang-Xi Li
Lijuan LijuanLijuan Lijuan
Lijuan Lijuan
LDLiwei Dong
Liwei Dong
HSHong-Guang Shi
Hong-Guang Shi
YPYu-Fei Pan
Yu-Fei Pan
HWHongyang Wang
Hongyang Wang

29 October 2024 in Clinical and Translational Discovery
Verified
Journal Article
Open access
SDShi‐Jia Dai
Shi‐Jia Dai
TJTian‐Yi Jiang
Tian‐Yi Jiang
ZYZhen‐Gang Yuan
Zhen‐Gang Yuan